Double CAR t attack: new trial targets leukemia that escapes first therapy

NCT ID NCT06408194

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-phase trial tests whether giving a second type of CAR T cell therapy (targeting CD22) after the standard CD19 CAR T therapy is safe and feasible for children and young adults with relapsed or hard-to-treat B-cell leukemia. About 20 participants will receive the standard CD19 CAR T cells first, followed by the experimental CD22 CAR T cells 28 to 42 days later. The main goals are to find the right dose and check for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD22 CAR T cells (a type of immune cell therapy)
What this could lead to: If it works, this could offer a new treatment option for leukemia patients who relapse after initial CAR T therapy.
What could go wrong: This is a very early phase 1 trial with only 20 participants, so it may not show clear benefit. There are also risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA LEUKEMIA

Contacts and locations

Locations

Stanford University
RECRUITING

Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.